134 related articles for article (PubMed ID: 30554955)
1. Design, synthesis of novel purin-6-one derivatives as phosphodiesterase 2 (PDE2) inhibitors: The neuroprotective and anxiolytic-like effects.
Huang XF; Cao YJ; Zhen J; Zhang DW; Kong R; Jiang WT; Xu Y; Song GQ; Ke HM; Liu L
Bioorg Med Chem Lett; 2019 Feb; 29(3):481-486. PubMed ID: 30554955
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel purine nucleoside derivatives as phosphodiesterase 2 (PDE2) inhibitors: Structure-based virtual screening, optimization and biological evaluation.
Qiu X; Huang Y; Wu D; Mao F; Zhu J; Yan W; Luo HB; Li J
Bioorg Med Chem; 2018 Jan; 26(1):119-133. PubMed ID: 29174506
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel N-1 substituted pyrazolopyrimidinones as potent, selective PDE2 inhibitors.
Morriello GJ; Dwyer MP; Chen Y; Ginetti AT; Xu S; Lu J; Abeywickrema P; Wang D; Crespo A; Cabalu TD; Wilson JE; Stachel SJ; Paone DV; Sinz C
Bioorg Med Chem Lett; 2021 Jul; 44():128082. PubMed ID: 33991626
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase 2 inhibitor Hcyb1 reverses corticosterone-induced neurotoxicity and depression-like behavior.
Zhu MJ; Shi J; Chen Y; Huang G; Zhu XW; Zhang S; Huang XF; Song GQ; Zhang HT; Ke HM; O'Donnell JM; Wang LQ; Xu Y
Psychopharmacology (Berl); 2020 Nov; 237(11):3215-3224. PubMed ID: 32926224
[TBL] [Abstract][Full Text] [Related]
5. Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy.
Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
Bioorg Med Chem Lett; 2013 Jun; 23(11):3443-7. PubMed ID: 23597790
[TBL] [Abstract][Full Text] [Related]
6. Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.
Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
Bioorg Med Chem Lett; 2013 Jun; 23(11):3438-42. PubMed ID: 23582272
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of phosphodiesterase 2 reverses gp91phox oxidase-mediated depression- and anxiety-like behavior.
Huang X; Xiaokaiti Y; Yang J; Pan J; Li Z; Luria V; Li Y; Song G; Zhu X; Zhang HT; O'Donnell JM; Xu Y
Neuropharmacology; 2018 Dec; 143():176-185. PubMed ID: 30268520
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.
Andrés JI; Buijnsters P; De Angelis M; Langlois X; Rombouts F; Trabanco AA; Vanhoof G
Bioorg Med Chem Lett; 2013 Feb; 23(3):785-90. PubMed ID: 23260348
[TBL] [Abstract][Full Text] [Related]
9. Indole acids as a novel PDE2 inhibitor chemotype that demonstrate pro-cognitive activity in multiple species.
Stachel SJ; Egbertson MS; Wai J; Machacek M; Toolan DM; Swestock J; Eddins DM; Puri V; McGaughey G; Su HP; Perlow D; Wang D; Ma L; Parthasarathy G; Reid JC; Abeywickrema PD; Smith SM; Uslaner JM
Bioorg Med Chem Lett; 2018 Apr; 28(6):1122-1126. PubMed ID: 29534798
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase-2 inhibitor reverses corticosterone-induced neurotoxicity and related behavioural changes via cGMP/PKG dependent pathway.
Xu Y; Pan J; Chen L; Zhang C; Sun J; Li J; Nguyen L; Nair N; Zhang H; O'Donnell JM
Int J Neuropsychopharmacol; 2013 May; 16(4):835-47. PubMed ID: 22850435
[TBL] [Abstract][Full Text] [Related]
11. The identification of a novel lead class for phosphodiesterase 2 inhibition by fragment-based drug design.
Forster AB; Abeywickrema P; Bunda J; Cox CD; Cabalu TD; Egbertson M; Fay J; Getty K; Hall D; Kornienko M; Lu J; Parthasarathy G; Reid J; Sharma S; Shipe WD; Smith SM; Soisson S; Stachel SJ; Su HP; Wang D; Berger R
Bioorg Med Chem Lett; 2017 Dec; 27(23):5167-5171. PubMed ID: 29113762
[TBL] [Abstract][Full Text] [Related]
12. The neuroprotective and antidepressant-like effects of Hcyb1, a novel selective PDE2 inhibitor.
Liu L; Zheng J; Huang XF; Zhu X; Ding SM; Ke HM; O'Donnell JM; Zhang HT; Song GQ; Xu Y
CNS Neurosci Ther; 2018 Jul; 24(7):652-660. PubMed ID: 29704309
[TBL] [Abstract][Full Text] [Related]
13. Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation.
Chłoń-Rzepa G; Jankowska A; Ślusarczyk M; Świerczek A; Pociecha K; Wyska E; Bucki A; Gawalska A; Kołaczkowski M; Pawłowski M
Eur J Med Chem; 2018 Feb; 146():381-394. PubMed ID: 29407965
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of 2-fluoro and 3-trifluoromethyl-phenyl-piperazinylalkyl derivatives of 1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione as potential antidepressant agents.
Zagórska A; Bucki A; Kołaczkowski M; Siwek A; Głuch-Lutwin M; Starowicz G; Kazek G; Partyka A; Wesołowska A; Słoczyńska K; Pękala E; Pawłowski M
J Enzyme Inhib Med Chem; 2016; 31(sup3):10-24. PubMed ID: 27353547
[TBL] [Abstract][Full Text] [Related]
15. PDE2 inhibition: potential for the treatment of cognitive disorders.
Gomez L; Breitenbucher JG
Bioorg Med Chem Lett; 2013 Dec; 23(24):6522-7. PubMed ID: 24189054
[TBL] [Abstract][Full Text] [Related]
16. Tumour growth inhibition and anti-angiogenic effects using curcumin correspond to combined PDE2 and PDE4 inhibition.
Abusnina A; Keravis T; Zhou Q; Justiniano H; Lobstein A; Lugnier C
Thromb Haemost; 2015 Feb; 113(2):319-28. PubMed ID: 25230992
[TBL] [Abstract][Full Text] [Related]
17. Computational determination of binding structures and free energies of phosphodiesterase-2 with benzo[1,4]diazepin-2-one derivatives.
Yang B; Hamza A; Chen G; Wang Y; Zhan CG
J Phys Chem B; 2010 Dec; 114(48):16020-8. PubMed ID: 21077589
[TBL] [Abstract][Full Text] [Related]
18. Cyclic GMP-mediated memory enhancement in the object recognition test by inhibitors of phosphodiesterase-2 in mice.
Lueptow LM; Zhan CG; O'Donnell JM
Psychopharmacology (Berl); 2016 Feb; 233(3):447-56. PubMed ID: 26525565
[TBL] [Abstract][Full Text] [Related]
19. The roles of phosphodiesterase 2 in the central nervous and peripheral systems.
Zhang C; Yu Y; Ruan L; Wang C; Pan J; Klabnik J; Lueptow L; Zhang HT; O'Donnell JM; Xu Y
Curr Pharm Des; 2015; 21(3):274-90. PubMed ID: 25159070
[TBL] [Abstract][Full Text] [Related]
20. Discovery of effective phosphodiesterase 2 inhibitors with antioxidant activities for the treatment of Alzheimer's disease.
Jiang MY; Han C; Zhang C; Zhou Q; Zhang B; Le ML; Huang MX; Wu Y; Luo HB
Bioorg Med Chem Lett; 2021 Jun; 41():128016. PubMed ID: 33838306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
